Fine Foods & Pharmaceuticals N.T.M. S.p.A (FF) Fair Value & Analysis
Consumer Defensive · IT · Market cap €204M
Fair value as of: Jun 24, 2026
From 16 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from €5.29 to €9.85 (+86.2%) since Jun 23, 2026. Share price −2.4% over the past month.
Price vs Fair Value (12 months)
12‑month range €7.48 – €11.57 · fair‑value band €6.90 – €12.81 · the €8.84 price screens below the €9.85 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Fine Foods & Pharmaceuticals N.T.M. S.p.A (FF) currently trades at €8.84, while our model-based Fair Value estimate is €9.85 — implying the stock looks roughly 11.4% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Fine Foods & Pharmaceuticals N.T.M. S.p.A generated revenue of €248M at a net margin of 2.8%. Revenue declined 7.2% year over year. It earns a return on equity of 5.2%. Net debt stands at €46.6M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract manufacturing and development of oral solid forms for the pharmaceutical and nutraceutical industries in Italy. The company offers pharmaceuticals, dietary supplements, and other nutraceutical products, as well as medical devices in the form of powder or granular mixtures, film-coated swallowable tablets, chewable tablets, effervescent tablets, hard gelatin capsules, and liquids in sachets, sticks, pill containers, jars, blisters, and strips packaging types. Its cosmetic products include toothpastes and gels, including those with microencapsulated active ingredients, single- and two-phase, alcoholic and non-alcoholic mouthwashes, and specific products for breath; skin care products, including emulsions, microemulsions, and gels; deodorants, such as solid sticks, roll-ons, and sprays; body cleansing products, including bath foams, shower gels, intimate cleansers, and liquid soaps; shampoos, conditioners, modelling wax…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Fine Foods & Pharmaceuticals N.T.M. S.p.A reported revenue of €252M in FY2025 versus €194M in FY2021, a compound +6.7%/yr. Reported net income was €10.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NSRGF | $97.58 | $65.41 | -33% |
| Foshan Haitian Flavouring and Food Company 603288 | ¥34.03 | ¥23.66 | -30% |
| Nestlé India Limited NESTLEIND | ₹1,386 | ₹278.10 | -80% |
| Grupo Bimbo, S.A. BIMBOA | 57.10 MXN | 45.03 MXN | -21% |
| Uni-President Enterprises Corp 1216 | 75.60 TWD | 55.53 TWD | -27% |
| Britannia Industries Limited BRITANNIA | ₹5,171 | ₹1,966 | -62% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Fine Foods & Pharmaceuticals N.T.M. S.p.A (FF) undervalued?
What is the fair value of FF?
What is the quality score of FF?
What is the revenue of Fine Foods & Pharmaceuticals N.T.M. S.p.A (FF)?
What is the net profit margin of FF?
Does Fine Foods & Pharmaceuticals N.T.M. S.p.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.